June 30, the last trading day of the first half of 2020. Judging from the performance of Shenyi class industry, pharmaceutical biology ranked first among all sectors with an increase of 42.30%, followed by food and beverage and leisure services, with an increase of 27.21% and 26.04% respectively.
In this context, the medical theme fund is a unique branch. Wind data shows that as of June 29, the average return of 369 general equity funds (A / C shares combined) has reached 21.22% this year. Among them, Chuang Jin Hexin healthcare industry a performed best, with a return rate of 78.70%; Guangfa healthcare a with a yield of 74.64%; ICBC Credit Suisse Frontier Medical, Baoying medical health, Shanghai, Hong Kong and Shenzhen, ICBC Credit Suisse pension industry and ICBC Credit Suisse medical health a also had a yield of more than 70%.
In the mixed fund, the medicine fund still dominates the screen. As of June 29, the average yield of 2861 hybrid funds this year has reached 15.25%, according to wind data. Among the top 20, except Guangfa new economy, Huatai Bairui incentive power a and Wanjia industry optimization, the remaining 17 are pharmaceutical theme funds. Among them, RONGTONG healthcare industry a performed the best with a yield of 70.04%.
Performance of index funds
At the same time, the performance of passive index funds, which benefit from structural market, is also commendable, especially the pharmaceutical theme ETF.
From the perspective of market performance, as of June 30, Cathay Pacific China Securities biomedical ETF had the highest increase since June 30, with an increase of 61.32%, followed by Huabao Zhongzheng medical ETF, with an increase of 60.87%. The performance of these two ETFs was far better than that of other stock ETFs. The third largest ETF was the China Securities 500 medical and health index, with an increase of 48.71%.
Structural opportunities are expected to continue
The pharmaceutical theme fund is obviously the big winner in the first half of the year. For the pharmaceutical sector, a well-known pharmaceutical fund manager in the industry said that in the short term, pharmaceutical stocks have indeed increased significantly. In the second half of the year, the expected rate of return should be reduced, but in the long run, pharmaceutical stocks should have relatively stable returns. He is optimistic about innovative drugs, medical devices, retail pharmacies and pharmaceutical consumption.
Source of this article: Ren Hui, editor in charge of China Securities News u00b7 China Securities Net_ NBJ9607